Vikran Engineering IPO Vs Anlon Healthcare IPO: GMP, Subscription, Price & Reviews Compared

Vikran Engineering vs. Anlon Healthcare: IPO Showdown!

The IPO market is heating up with two compelling offerings: Vikran Engineering and Anlon Healthcare. Which one should you invest in? Let's break down the key details to help you decide.

IPO Size and Price Band

• Vikran Engineering: A ₹772 crore issue (₹721 crore fresh issue + ₹51 crore offer-for-sale). Price band: ₹92 - ₹97 per share. Minimum investment: ₹14,356 (148 shares).
• Anlon Healthcare: A ₹121.03 crore issue. Price band: ₹86 - ₹91 per share. Minimum investment: ₹14,924 (164 shares).

Grey Market Premium (GMP) - A Glimpse into Market Sentiment

• Vikran Engineering: GMP of ₹110, indicating a potential 13.4% premium over the issue price.
• Anlon Healthcare: GMP of ₹96, suggesting a smaller 5.49% premium.

Expert Opinions: Weighing the Pros and Cons

Vikran Engineering:

• Lakshmishree Investment (Anshul Jain): "Subscribe" rating for long-term investors, citing strong execution, experienced management, and exposure to a high-growth sector.
• Swastika Investmart (Shivani Nyati): Highlights Vikran as a fast-growing EPC player with impressive revenue growth (32.17% CAGR) and a substantial order book (over ₹2,442 crore). Views the IPO as fairly priced.
• Positive outlook from multiple brokerages: BP Equities, Arihant Capital, Adroit Financial Services, AUM Capital, and Canara Bank Securities all recommend a "Subscribe".

Anlon Healthcare:

• Anand Rathi Research: "Subscribe - Long Term" rating, emphasizing the scalable business model and high entry barriers within the sector. Valued at 19x FY25 earnings.
• Arihant Capital: "Subscribe" rating, highlighting the diverse product portfolio, regulatory approvals, and planned capacity expansion. However, they acknowledge long client approval cycles as a potential risk. Valued at 24x FY25 earnings.

Company Overview and Use of Proceeds

• Vikran Engineering: A Mumbai-based infrastructure EPC company with a proven track record. IPO proceeds will primarily fund working capital and general corporate purposes.
• Anlon Healthcare: A chemical manufacturer specializing in high-purity pharmaceutical intermediates. IPO proceeds will support capacity expansion, debt repayment, working capital, and general corporate needs.

Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Consult with a qualified financial advisor before making any investment decisions.

Author: Mohammad Haris, Deputy News Editor (Business) at News18.com